Epidemiology of Complex Disease

The Selenium and Vitamin E trial in non-muscle invasive bladder cancer (SELENIB)

SELENIB is a randomised double-blinded placebo-controlled trial. It investigates whether selenium and/or vitamin E (α-tocopherol) supplementation reduces the risk of recurrence and progression in patients with non-muscle invasive bladder cancer. Newly diagnosed patients are being randomised in a 2x2 factorial design. They are receiving daily supplementation with selenium or placebo and vitamin E or placebo for up to five years and will be followed up by routine cystoscopic surveillance. The primary outcome measure is recurrence-free interval. The principal secondary outcome is progression-free interval. We aim to recruit 516 patients.

Research group 

Prof. Maurice Zeegers
Prof. K.K. Cheng
Rik Bryan, MD, PhD
Nadezhda Lipunova, MSc


Prof. Maurice Zeegers